SMi conference speech on targeting the tumor microenvironment

Jun 1, 2017

Copenhagen, Denmark – June 1, 2017: Professor Mads Hald Andersen, CSO of IO Biotech and Director of CCIT (Center for Cancer Immune Therapy) at University of Copenhagen Herlev Hospital in Denmark has been invited to speak on day 2 at the SMi conference in London, Sept 2017.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

November 9, 2021

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

September 14, 2021

back to news overview